Tvardi Therapeutics, Inc.
TVRD
Rank in Stocks
#27419
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages... Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Share Price
$1.18
Last synced: 2026-11-13
Market Cap
$14.93M
Change (1 day)
1.72%
Change (1 year)
-70.72%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Tvardi Therapeutics, Inc. (TVRD)
Category
Healthcare
Operating Margin for Tvardi Therapeutics, Inc. (TVRD)
Operating Margin as of November 2026 TTM: 0.00%
According to Tvardi Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Tvardi Therapeutics, Inc. from 2020 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -781.57% | 34.89% |
| 2023 | -579.43% | 177.13% |
| 2022 | -209.08% | -45.95% |
| 2021 | -386.85% | -9,795.49% |
| 2020 | 3.99% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -195.39% | - |
US
|
|
| 33.87% | - |
US
|
|
| -116.04% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Tvardi Therapeutics, Inc.'s operating margin
What was Tvardi Therapeutics, Inc.'s operating margin in 2025?
In 2025, Tvardi Therapeutics, Inc.'s operating margin was 0.00%, compared with -781.57% in 2024.
How has Tvardi Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Tvardi Therapeutics, Inc.'s operating margin was highest in 2020 (3.99%) and lowest in 2024 (-781.57%).
How does Tvardi Therapeutics, Inc.'s operating margin compare with similar companies?
Tvardi Therapeutics, Inc.'s operating margin (0.00%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.